Compare GNLN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLN | KALA |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.5M |
| IPO Year | 2019 | 2017 |
| Metric | GNLN | KALA |
|---|---|---|
| Price | $0.76 | $3.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 164.5K |
| Earning Date | 12-01-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.07 |
| 52 Week High | $139.60 | $191.00 |
| Indicator | GNLN | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 27.01 | 77.25 |
| Support Level | N/A | $2.07 |
| Resistance Level | $3.28 | $3.71 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.02 | 0.38 |
| Stochastic Oscillator | 18.11 | 73.26 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). It serves specialty retailers, smoke shops, head shops, convenience stores, and consumers. Geographically, it operates in United States, Canada, and Europe. It derives majority revenue from the United States. Its two operating segments are: Wholesale and Distribution, which includes legacy e-commerce and drop-ship operations; and Digital Assets, which includes digital asset treasury activities including acquisition, staking and validator participation related to BERA.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.